Literature DB >> 24534547

Liver injury is common among chronic abusers of ketamine.

Grace Lai-Hung Wong1, Yuk-Him Tam2, Chi-Fai Ng3, Anthony Wing-Hung Chan4, Paul Cheung-Lung Choi4, Winnie Chiu-Wing Chu5, Paul Bo-San Lai6, Henry Lik-Yuen Chan1, Vincent Wai-Sun Wong7.   

Abstract

Abuse of ketamine leads to liver injury. We investigated the histopathologic and radiologic features of ketamine abusers with significant liver injury in a cross-sectional survey of 297 consecutive chronic abusers of ketamine with urinary tract dysfunction. Liver biopsy and magnetic resonance cholangiopancreatography were performed in patients with liver injury (concentrations of bilirubin, alkaline phosphatase, and/or alanine aminotransferase >2-fold the upper limit of normal). The prevalence of liver injury was 9.8% (all cases cholestatic). Bile duct injury was observed in all 7 patients assessed by liver biopsy. Two patients had bridging fibrosis despite their young age. Three of 6 patients who underwent magnetic resonance cholangiopancreatography examination were found to have prominent or dilated common bile ducts without obstructions or extrinsic compressions. Ketamine abuse therefore appears to lead to common bile duct dilatation, microscopic bile duct injury, and even significant liver fibrosis.
Copyright © 2014 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Clinical Report; Drug Abuse; Hepatobiliary Disease; Liver Damage

Mesh:

Substances:

Year:  2014        PMID: 24534547     DOI: 10.1016/j.cgh.2014.01.041

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  11 in total

Review 1.  Use of Ketamine in Elderly Patients with Treatment-Resistant Depression.

Authors:  Carolina Medeiros da Frota Ribeiro; Patricio Riva-Posse
Journal:  Curr Psychiatry Rep       Date:  2017-11-15       Impact factor: 5.285

2.  Bile Duct Injury due to Drug Induced Liver Injury.

Authors:  Priya Grewal; Jawad Ahmad
Journal:  Curr Hepatol Rep       Date:  2019-07-15

Review 3.  Intravenous hypnotic regimens in patients with liver disease; a review article.

Authors:  Hassan Soleimanpour; Saeid Safari; Farzad Rahmani; Asghar Jafari Rouhi; Seyed Moayed Alavian
Journal:  Anesth Pain Med       Date:  2015-02-24

Review 4.  Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists.

Authors:  Steven P Cohen; Anuj Bhatia; Asokumar Buvanendran; Eric S Schwenk; Ajay D Wasan; Robert W Hurley; Eugene R Viscusi; Samer Narouze; Fred N Davis; Elspeth C Ritchie; Timothy R Lubenow; William M Hooten
Journal:  Reg Anesth Pain Med       Date:  2018-07       Impact factor: 6.288

5.  Safety and Efficacy of Ketamine-Fentanyl-Dexmedetomidine-Induced Anesthesia and Analgesia in Neonatal and Aged Rats.

Authors:  Xuhui Zhou; Wenlong Li; Hao Wang; Chunzhu Li; Hong Jiang
Journal:  Dose Response       Date:  2021-12-13       Impact factor: 2.658

6.  Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in patients with chronic liver disease.

Authors:  Lukas Hartl; Katharina Haslinger; Martin Angerer; Georg Semmler; Mathias Schneeweiss-Gleixner; Mathias Jachs; Benedikt Simbrunner; David Josef Maria Bauer; Ernst Eigenbauer; Robert Strassl; Monika Breuer; Oliver Kimberger; Daniel Laxar; Katharina Lampichler; Emina Halilbasic; Albert Friedrich Stättermayer; Ahmed Ba-Ssalamah; Mattias Mandorfer; Bernhard Scheiner; Thomas Reiberger; Michael Trauner
Journal:  Hepatology       Date:  2022-05-21       Impact factor: 17.298

Review 7.  Ketamine: 50 Years of Modulating the Mind.

Authors:  Linda Li; Phillip E Vlisides
Journal:  Front Hum Neurosci       Date:  2016-11-29       Impact factor: 3.169

8.  The Risk of Upper Urinary Tract Involvement in Patients With Ketamine-Associated Uropathy.

Authors:  Chi-Hang Yee; Jeremy Yuen-Chun Teoh; Pui-Tak Lai; Vivian Yee-Fong Leung; Winnie Chiu-Wing Chu; Wai-Man Lee; Yuk-Him Tam; Chi-Fai Ng
Journal:  Int Neurourol J       Date:  2017-06-21       Impact factor: 2.835

9.  Risk of Renal Function Decline in Patients with Ketamine-Associated Uropathy.

Authors:  Shih-Hsiang Ou; Ling-Ying Wu; Hsin-Yu Chen; Chien-Wei Huang; Chih-Yang Hsu; Chien-Liang Chen; Kang-Ju Chou; Hua-Chang Fang; Po-Tsang Lee
Journal:  Int J Environ Res Public Health       Date:  2020-10-04       Impact factor: 3.390

10.  Repeated or Continuous Medically Supervised Ketamine Administration Associated with Hepatobiliary Adverse Events: A Retrospective Case Series.

Authors:  Samantha Cotter; Jennie Wong; Neha Gada; Rajdeep Gill; S Christopher Jones; Grace Chai; Daniel Foster; Mark Avigan; Mallika Mundkur
Journal:  Drug Saf       Date:  2021-10-26       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.